Stock Analiz

Celldex Therapeutics, Inc. (CLDX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Celldex Therapeutics’s revenue went from $7M in fiscal 2016 to $2M in fiscal 2025, a decline of about 15.2% a year.

Net income in fiscal 2025 was -$259M, a net margin of -16748.0%; the best year in this period was 2019 with -$51M.

Over the twelve months to September 30, 2026, revenue was $158000 and net income -$309M.

Free cash flow was -$214M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 881% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $7M162017: $13M172018: $10M182019: $4M192020: $7M202021: $5M212022: $2M222023: $7M232024: $7M242025: $2M25$2M
Net income
2016: -$129M162017: -$93M172018: -$151M182019: -$51M192020: -$60M202021: -$71M212022: -$112M222023: -$141M232024: -$158M242025: -$259M25-$259M
Free cash flow
2016: -$116M162017: -$102M172018: -$76M182019: -$47M192020: -$42M202021: -$62M212022: -$106M222023: -$109M232024: -$160M242025: -$214M25-$214M
EPS (diluted)
2016: $-18.99162017: $-10.86172018: $-0.01182019: $-0.00192020: $-0.00202021: $-0.00212022: $-0.00222023: $-2.92232024: $-2.45242025: $-3.9025$-3.90

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$158000$2M$7M$7M$2M$5M$7M$4M$10M$13M$7M
Gross profit—$1M$7M$7M$2M$5M$7M$3M$9M$12M$5M
Operating income-$334M-$287M-$195M-$155M-$115M-$71M-$63M-$55M-$156M-$122M-$133M
Net income-$309M-$259M-$158M-$141M-$112M-$71M-$60M-$51M-$151M-$93M-$129M
EPS (diluted)$-4.31$-3.90$-2.45$-2.92$-0.00$-0.00$-0.00$-0.00$-0.01$-10.86$-18.99
R&D$283M$245M$164M$118M$82M$53M$43M$43M$66M$96M$103M
Revenue growth—−78.0%+2.0%+192.0%−49.3%−37.3%+107.6%−62.5%−25.1%+87.8%+23.8%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$252M-$211M-$158M-$107M-$104M-$61M-$40M-$46M-$75M-$100M-$113M
Capital spending-$8M-$3M-$2M-$2M-$2M-$1M-$2M-$731000-$813000-$2M-$3M
Free cash flow-$260M-$214M-$160M-$109M-$106M-$62M-$42M-$47M-$76M-$102M-$116M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$37M$36M$34M$24M$16M$9M$4M$5M$8M$12M$15M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$519M$725M$424M$305M$408M$194M$64M$94M$139M$190M
Debt—$2M$4M$3M$4M$3M$3M$4M———
Equity—$527M$747M$429M$326M$419M$209M$94M$124M$236M$265M
Total assets—$583M$792M$466M$353M$445M$236M$123M$156M$316M$383M
Shares (diluted)79M66M64M48M47M43M30M15M10M9M7M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—87.1%97.2%95.6%95.8%97.9%97.3%97.2%92.7%94.5%76.4%
Operating margin-211684.8%-18599.8%-2778.9%-2245.3%-4889.0%-1531.8%-854.1%-1540.2%-1640.1%-953.7%-1958.7%
Net margin-195608.9%-16748.0%-2248.8%-2054.8%-4765.6%-1516.0%-805.9%-1424.0%-1585.1%-730.1%-1894.0%
FCF margin-164391.8%-13829.1%-2274.9%-1585.2%-4478.6%-1336.4%-565.6%-1319.5%-797.3%-798.2%-1706.3%
ROIC—-54.3%-26.0%-35.8%-27.6%-16.8%-29.2%-44.5%-125.5%-40.8%-39.6%
ROE—-49.1%-21.1%-33.0%-34.4%-16.8%-28.5%-54.1%-121.9%-39.4%-48.4%

Frequently asked questions

What is Celldex Therapeutics’s annual revenue?

$2M in fiscal 2025 and $158000 over the twelve months to September 30, 2026.

How much profit does Celldex Therapeutics make?

Net income was -$259M in fiscal 2025 (net margin -16748.0%).

Is Celldex Therapeutics’s revenue growing?

No: revenue fell 78.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.